Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: Review of the evidence

Bone

Volumn 44, Issue 5, 2009, Pages 744-751

  Inderjeeth, Charles A ^a,b   Foo, Adrian C H ^b   Lai, Michelle M Y ^b   Glendenning, Paul ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b North Metropolitan Area Health Service   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Efficacy; Fracture risk; Hip fracture; Non vertebral fracture; Old old; Osteoporosis; Pharmacological treatment

Indexed keywords

ALENDRONIC ACID; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID;

AGED; BACKACHE; CATARACT; CLINICAL TRIAL; COCHRANE LIBRARY; CONSTIPATION; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FRACTURE REDUCTION; FRAGILITY FRACTURE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL TOXICITY; HEARING IMPAIRMENT; HIP FRACTURE; HUMAN; MEDLINE; NAUSEA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRURITUS; REVIEW; RISK REDUCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; WEIGHT REDUCTION;

ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; TERIPARATIDE; THIOPHENES;

EID: 63449117928     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.12.003     Document Type: Review

References (64)

1. De Laet C.E., Van Hout B.A., Burger H., et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J. Bone Miner. Res. 13 (1998) 1587-1593
2. Hui S.L., Slemenda C.W., and Johnston Jr. C.C. Age and bone mass as predictors of fracture in a prospective study. J. Clin. Invest. 81 (1988) 1804-1809
3. Sanders K.M., Seeman E., Ugoni A.M., et al. Age- and gender-specific rate of fractures in Australia: a population based study. Osteoporos. Int. 10 (1999) 240-247
4. Kanis J.A., Johnell O., and Oden A. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos. Int. 12 (2001) 989-995
5. Black D.M., Steinbuch M., and Palermo L. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos. Int. 12 (2001) 519-528
6. Ettinger M.P. Aging bone and osteoporosis: strategies for preventing fractures in the elderly. Arch. Intern. Med. 63 (2003) 2237-2246
7. Looker A.C., Johnston Jr. C.C., Wahner H.W., et al. Prevalence of low femoral bone density in older US women from NHANES III. J. Bone Miner. Res. 10 (1995) 796-802
8. Kanis J.A., Glüer C.C., for the Committee Scientific Advisors, and International Osteoporosis Foundation. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos. Int. 11 (2000) 192-202
9. Tinetti M., Speechley M., and Ginter S. Risk factors for falls among elderly persons living in the community. N. Eng. J. Med. 319 (1988) 1701-1707
10. Cummings S.R., Nevitt M.C., Browner W.S., et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fracture Research Group. N. Eng. J. Med. 332 (1995) 767-773
11. Centre for Disease Control and Prevention. Fatalities and injuries from falls among older adults - United States 1993-2003. MMWR 55 (2006) 1221-1224
12. Tinetti M.E., Speechley M., and Ginter S.F. Risk factors for falls among elderly persons living in the community. N. Eng. J. Med. 317 (1988) 1701-1707
13. Tinetti M.E., and Williams C.S. The effect of falls and fall injuries on functioning in community-dwelling older persons. J. Gerontol., A, Biol. Sci. Med. Sci. 53 (1998) M112-M119
14. Kanis J.A., and McCloskey E.V. Epidemiology of vertebral fractures. Bone 3 Suppl 2 (1992) S1-S10
15. Melton III L.J., Lane A.W., Cooper C., et al. Prevalence and incidence of vertebral deformities. Osteoporos. Int. 3 (1993) 113-119
16. van Staa T.P., Dennison E.M., Leufkens H.G., et al. Epidemiology of fractures in England and Wales. Bone 29 (2001) 517-522
17. Van der K.l.i.f.t., De Laet C.E., McCloskey E.V., et al. The incidence of vertebral fractures in men and women: the Rotterdam study. J. Bone Miner. Res. 17 (2002) 1051-1056
18. The European Prospective Osteoporosis Study (EPOS) Group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study. J. Bone Miner. Res. 17 (2002) 716-724
19. Lord S.R. Hip fractures: changing patterns in hospital bed use in NSW between 1979-1990. Aust. N. Z. J. Surg. 63 (1993) 352-355
20. Jones G., Nguyen T., and Sambrook P.N. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos. Int. 4 (1994) 277-282
21. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat 2002. World population prospects: the 2002 revision of world urban prospects (online). Available at http://esa.un.org/unpp. Accessed September 23, 2007.
22. Sanders K.M., Nicholson G.C., Ugoni A.M., et al. Health burden of hip and other fractures in Australia beyond 2000: projections based on the Geelong osteoporosis study. Med. J. Aust. 170 (1999) 467-470
23. Barrett J.A., Baron J.A., Karagas M.R., et al. Fracture risk in the US Medicare population. J. Clin. Epidemiol. 52 (1999) 243-249
24. Cooper C., and Melton III L.J. Epidemiology of osteoporosis. Trends Endocrinol. Metab. 314 (1992) 224-229
25. Gullberg G., Johnell O., and Kanis J.A. Worldwide projections for hip fracture. Osteoporos. Int. 7 (1997) 407-413
26. Birge S.J., Morrow-Howell N., and Proctor E.K. Hip fracture. Clin. Geriatr. Med. 10 (1994) 589-609
27. Magazier J., Hawkes W., Hebel H.R., et al. Recovery from hip fracture in eight areas of function. J. Gerontol., A, Biol. Sci. Med. Sci. 59 (2000) M498-M507
28. Tinetti M.E., and Williams C.S. Falls injuries due to falls, and the risk of admission to a nursing home. N. Eng. J. Med. 337 (1997) 1279-1284
29. Cummings S.R., Kelsey J.L., Nevitt M.C., et al. Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol. Rev. 7 (1985) 178-208
30. Center J.R., Nguyen T.V., Schneider D., et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353 (1999) 878-882
31. Randell A., Sambrook P.N., Nguyen T.V., et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos. Int. 5 (1995) 427-432
32. Access Economics Pty Ltd. The burden of brittle bones: costing osteoporosis in Australia. Available online at http://www.osteoporosis.org.au/files/research/archive/burdenbrittle_oa_2001.pdf. Accessed 12 September 2007.
33. Cummings S.R., Rubin S.M., and Black D. The future of hip fractures in the United States. Numbers, costs and potential effects of postmenopausal oestrogen. Clin. Orthop. 252 (1990) 163-166
34. Stevenson M., Lloyd Jones M., De Nigris E., et al. A systematic review and economic evaluation of Alendronate, Etidronate, Risedronate, Raloxifene and Teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol. Assess. 9 (2005) 1-160
35. Borgström F., Johnell O., Kanis J.A., et al. At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos. Int. 17 (2006) 1459-1471
36. Borgström F., Jönsson B., Ström O., et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos. Int. 17 (2006) 1781-1793
37. Seeman E., Vellas B., Benhamou C., et al. Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in women 80 years of age and older. J. Bone Miner. Res. 21 (2006) 1113-1120
38. Boonen S., McClung, Eastell R., et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women age 80 and older: implications for the use of antiresorptive agent in the old and oldest old. J. Am. Geriatr. Soc. 52 (2004) 1832-1839
39. Boonen S., Marin F., Mellstrom D., et al. Safety and efficacy of teriparatide in elderly women with established Osteoporosis: bone anabolic therapy from a geriatric perspective. J. Am. Geriatr. Soc. 54 (2006) 782-789
40. Ensrud K.E., Black D.M., Palermo L., et al. Treatment with alendronate prevents fractures in women at highest risk: results from the fracture intervention trial. Arch. Int. Med. 157 (1997) 2617-2624
41. McCloskey E.V., Beneton M., Charlesworth D., et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled study. J. Bone Miner. Res. 22 (2007) 135-141
42. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Eng. J. Med. 344 (2001) 333-340
43. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduces the risk of non vertebral fracture in post menopausal women with osteoporosis: treatment of peripheral osteoporosis. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
44. Meunier P.J., Roux C., Seeman, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Eng. J. Med. 350 (2004) 459-468
45. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with post-menopausal osteoporosis: a randomised controlled trial. JAMA 28 (1999) 1344-1352
46. Reginster J.Y., Minne H.W., Sorenson O.H., et al. Randomised trial of the effects of risedronte on vertebral fracture in women with established postmenopausal osteoporosis. Osteoporos. Int. 11 (2000) 83-91
47. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone density in post-menopausal women with osteoporosis. N. Eng. J. Med. 344 (2001) 1434-1441
48. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
49. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Eng. J. Med. 356 (2007) 1809-1821
50. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Eng. J. Med. 357 (2007) 1799-1809
51. Greenspan S.L., Schneider D.L., McClung M.R., et al. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. Ann. Intern. Med. 136 (2002) 742-746
52. Riggs B.L., Warner H.W., Seeman E., et al. Changes in bone mineral density of the proximal femur and spine with ageing: differences between the postmenopausal and senile osteoporosis syndromes. J. Clin. Invest. 71 (1982) 716-723
53. Melton III L.J., Kan S.H., Wahner H.W., et al. Lifetime fracture risk: an approach to hip fracture risk assessment based on bone mineral density and age. J. Clin. Epidemiol. 41 (1988) 985-994
54. Sambrook P.N., Cameron I.D., Chen J.S., et al. Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos. Int. 18 (2007) 603-610
55. Manolagas S.C., and Jilka R.L. Bone marrow, cytokines and bone remodelling. Emerging insights into pathophysiology of osteoporosis. N. Eng. J. Med. 332 (1995) 305-311
56. Canalis E., Hott M., Deloffre P., et al. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 18 (1996) 517-523
57. Baron R., and Tsuderos Y. In vitro effects of S12911-2 on osteoclast function and bone macrophage differentiation. Eur. J. Pharmacol. 450 (2002) 11-17
58. Jarvinen T.L.N., Sievanen H., Khan K.M., et al. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ 336 (2008) 124-126
59. Greenspan S.L., Myers E.R., Maitland L.A., et al. Fall severity and bone mineral density s risk factors for hip fracture in ambulatory elderly. JAMA 271 (1994) 128-133
60. Kannus P., Sievanen H., Palvanen M., et al. The prevention of falls and consequent injuries in elderly people. Lancet 366 (2005) 1885-1893
61. Bischoff-Ferrari H.A., Giovanucci E., Willett W., et al. Estimation of optimal serum concentration of 25 hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84 (2006) 18-28
62. Oliver D., Connelly J.B., Victor C.R., et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ 334 (2007) 82
63. Parker M.J., Gillespie W.J., and Gillespie L.D. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 332 (2006) 571-574
64. Sawka A.M., Boulos P., Beattie K., et al. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J. Clin. Epidemiol. 60 (2007) 336-344